Tang Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tang Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-45,000	Closed	-$9.01M	–	101
2023 Q1	$9.01M	Sell	45,000 -60,000	-57%	-$12.6M	1.34%	28
2022 Q4	$25M	Buy	105,000 +5,000	+5%	+$1.07M	3.63%	6
2022 Q3	$20M	Buy	+100,000	New	+$19.1M	2.45%	12

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tang Capital Management's ALNY Position: Q2 2023 in Review

Tang Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 45,000 shares — an estimated $9.01M sold.

Tang Capital Management first reported a position in ALNY in Q3 2022 and held it in 3 quarters. The position peaked at $25M in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Tang Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Tang Capital Management sold 45,000 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $9.01M.
Tang Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Tang Capital Management's Alnylam Pharmaceuticals position peaked at $25M in Q4 2022.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.